TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in acetylcholinesterase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with severe asthma according to frequency of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiac function and ejection fraction changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Reduction in Whole Brain Monoamine Oxidase (MAO)-B Availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients who discontinued due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Spatial and temporal gait parameters - gait velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Anterior chamber depth (ACD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: uptake of [68Ga]Ga-DOTA-(RGD)2 in the lung parenchyma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of telomeric abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collection of serious adverse events of AMI
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of repeat dosing
Endpoint domain: Adverse events/effects
Primary endpoint: mitochondrial oxidative phosphorylation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: production of reactive oxygen species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Cytogenetic Response (CCyR) at Year 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerance of different dose levels
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of study medication
Endpoint domain: Adverse events/effects
Primary endpoint: Smooth pursuit eye movement measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P50 gating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P300 component evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ecchymosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Approximation scale changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skin-to-skin contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported number of sick-days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximum Standardized Uptake Value of 3-[18F]-FACBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First quartile excess weight loss (0-11% EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: episode of intraoperative hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: excess weight loss (%EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the revised HOME-CoV score strategy
Endpoint domain: Adverse events/effects
Primary endpoint: 2-level Composite Responders for the Target Buttock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive Mechanical ventilation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: RAND-MOS36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short Self Efficacy scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of tinnitus on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Clinical global impression scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of severe infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Spontaneous preterm birth before 37 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Target-vessel failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of any SAEs related to the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any Grade 3 or higher adverse reactions related to the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of solicited local and systemic AEs within 1 week after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 2 or higher soft tissue attachments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: NIBUT in Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of alcohol entry into the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manometric indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of immune markers of acute lung transplant rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Oswestry from baseline to 10-weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Intensity from baseline to 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fatigue from baseline to 10 weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: PaO2 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disappearance of proteinuria/hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal function (measured by Cr-EDTA-Cl- GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal biopsy findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of time with gastric pH above 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharmacokinetics (PK) of darbepoetin alfa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Fluoride concentration in saliva before brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride concentration in saliva 5 min after brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride concentration in saliva 15 min after brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride concentration in saliva 30 min after brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride concentration in dental biofilm (fluid fraction) before brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of 7-day Point Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response Rate of Cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neutrophil expression of ICAM-1, L-selectin, FasR and TRAIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recommended Phase II Dose (RPTD, RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four Square Step test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall digestive comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Menopause Symptoms Rating Scale (MSRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Marital Adjustment Scale (MAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of REM use
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of triple-negative breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance of ultrasound imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ESA dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Solicited Injection Site or Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sexual frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post-operative low cardiac output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of range of motion after 4-week training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of muscle strength after 4-week training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of shoulder complex kinematics after 4-week training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of muscular activities after 4-week training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skin necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful nasotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: difficult intubation scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence / absence of EFL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Authorization Rates for Solid Organ Donation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Thyroid goiter confirmed by ultrasonographic thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid dysfunction confirmed by serum concentrations of FT3, FT4, TSH, TPOAB and TGAb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Evaluation of neuropsychological development of children at age 2
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: BOLD phMRI signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patent parasitemia via peripheral blood smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Episodes of Intermittent Hypoxia Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Seconds of Intermittent Hypoxia Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: anterior chamber depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Job loss
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Solicited symptoms after immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in cutaneous blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postoperative stroke
Endpoint domain: Mortality/survival
Primary endpoint: Rate of complete cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of trial procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of trial procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From DB Baseline in Conners' Adult ADHD Rating Scale (CAARS) Total Score at DB Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pocket probing depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Assessment (FMA) motor function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal and minimal diameter of the inferior caval vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MNSI score for neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major adverse aorta-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Brief Pain Inventory value
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: high quality chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest compressions rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD34+ progenitor cell blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fracture displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Crestal Horizontal Ridge Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to recovery of Sp02
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial bio markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants completing the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood phosphorus concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Selective Control of the Extremity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of IIEF-EF domain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: false positive rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAS Pediatric Asthma Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suplemental Oxigen day use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With HIV-1 RNA Levels < 50 Copies/mL at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA < 200 Copies/mL at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse event data
Endpoint domain: Adverse events/effects
Primary endpoint: Analysis of cartilage lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score of Fahn-Tolosa-Marin scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Relief of pain or discomfort in the chest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum antibody levels pre and post vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Mean Level of Circulating Follicular Helper T (TFH) Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in remineralization of white spot lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD signal change during breast palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good knowledge of diabetes management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Good compliance with diabetes management
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Good control of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Movements Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Mean Defocus Curve (AUC) at High Luminance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in GERDDQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oral manifestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: spot urine oxalate to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number and intensity of serious and non-serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Receptive and expressive language abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication possession ratio (MPR)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: gaps in medicines use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: persistence in medicines use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer of 1:40 or Greater Against the Influenza H1N1 2009 Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With 4-Fold or Greater HAI Antibody Titer Increases Against the Influenza H1N1 2009 Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Numbers of HCV-specific gut mucosal B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transcriptomic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Cognition on MCCB
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Managing Emotions on MSCEIT
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Genomic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: De novo somatic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retention to the LARKSPUR Study at 8 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention to the LARKSPUR Study at 12 weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Constant-Murley shoulder outcome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microvasculature blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Connectedness to Nature Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evaluation of Discomfort and well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogic Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes